




# Economic & Environmental Footprint of Novartis in Ireland



## Novartis Ireland's Key Therapy Areas



## Novartis Medicines Manufacturing in Ireland (Sterling Pharma Solutions)



#NovartisIrelandInspires



Novartis Elm Park

# Who we are

Novartis has been present in Ireland since the 1950s and we currently employ approximately 900 people with many of these jobs of a highly skilled, high-value nature.

## Novartis Commercial Operations

We are proud that our medicines reach over a quarter of a million people in Ireland every year.<sup>1</sup> Healthcare systems globally, including those in Ireland, face significant pressure due to challenges posed by an ageing population and the management of chronic disease. At Novartis International we're working hard to address these issues and add value to the healthcare system through our range of medicines. As well as medicines, we are providing "beyond the pill" healthcare solutions that are fit for the future, for example new technologies, innovative devices, and patient-centric services. #NovartisIrelandInspires

## Novartis Corporate Centre

Established in 2013, the Novartis Corporate Centre provides a range of services to Novartis on a global scale. The hub, located in Dublin, is home to a wealth of talent that drives innovation, standardisation, and top-tier service delivery. The centre leverages on Ireland's substantial life science and tech ecosystem using deep pharma knowledge and business partnering to create business and healthcare solutions at a global level.

Strategically situated between Novartis Headquarters in Switzerland and the US, the Dublin-based Corporate Centre is one of the centres for Global Drug Development, hosting over 250 individuals responsible for conducting global clinical trials and Research & Development (R&D).

The site currently employs people from over 50 nationalities, speaking 32 languages.<sup>2</sup>


We are proud of our graduate programme which has offered career opportunities for many graduates in medical, marketing and commercial roles.

We are committed to fostering an inclusive workplace, with a focus on sustainability. Already, 45%<sup>3</sup> of our management team in Ireland is female, and our plan is to have gender parity by 2027.

## Manufacturing at Ringaskiddy – Sterling Pharma Solutions

In 2022, Novartis announced it had reached an agreement with Sterling Pharma Solutions, a leading global development and manufacturing company, to produce medicine for Novartis (active pharmaceutical ingredient (API)) in Ireland. Sterling Pharma Solutions are producing Novartis APIs for cardiology, immunology and oncology medicines. In 2022, the production facilities secured a \$16million investment from Novartis, to manufacture a significant cardiovascular medicine on the site.

Novartis Ireland has a global reach, providing its services worldwide from the centre of Europe.



## Novartis Economic Footprint



employing  
circa  
**900** people<sup>4</sup>



market position (Rx)  
**in Ireland #2**<sup>5</sup>

Societal impact of **Novartis medicines** in Ireland  
**€853m**<sup>6</sup>



GDP contribution from **Novartis'** work in Ireland  
**€533m**<sup>7</sup>

an estimated  
3 packs per  
minute supplied  
to **patients in  
Ireland** in 2023<sup>9</sup>



more than  
**270,000**  
**patients** supplied with  
**Novartis medicines**  
in 2023<sup>8</sup>



#NovartisIrelandInspires  
#ThriveTogether

# Healthcare Ecosystem in Ireland<sup>4</sup>

## Healthcare System

- Keeping HF patients out of hospital (community titration & blood monitoring)
- Working with SFI (research centre FutureNeuro):



**LEGEND** (The Learning Health System in a Digital hospital) is developing a prototype that will integrate electronic patient records (EPR) to use with research analytics.

- Novartis Patient Support Services
- On-time supply of medicines
- Webinar series on health economic perspectives in key areas (e.g. cancer management, value-based healthcare)

## Medical Technology

- Heart Failure Online Symptom Tracker
- Dontforget.ie Medication Reminder Service for all medicines in Ireland
- Disease Management Mobile Apps in psoriasis, MS and ITP



## Academia

- Academic research partnerships nationwide
- Collaboration with TILDA (The Irish Longitudinal Study on Ageing), Trinity College Dublin
- PhD programmes with RCSI, Maynooth, UCD, UL, TUD
- Health Economics Internship Programme with NUI Galway (since 2001)\*
- Tangent Accelerator Programme for start-ups, run by Tangent, Trinity College Dublin's Ideas Workspace
- Collaborating with RCSI on National Healthcare Outcomes Conference



## Healthcare Professionals

- Multiple research partnerships nationwide
- Supporting healthcare professionals in their education and development



## Patient Community

- LEAP is a Novartis developed patient support platform, developed in Ireland for global outreach. The digital system helps patients to get their prescribed treatment and stay up to date with the latest treatment options.
- Collaborating on a pilot study with Arthritis Ireland using AI to free up nurse time on the phone in 3 centres.



## Partnerships

- In partnership with RCSI, Novartis has hosted for the past three years a health awareness conference. More than 2,500 people registered for the events covering cancer and chronic diseases.



# Novartis Ireland

## Indigenous Irish Companies

- Partnership with HealthBeacon Smart Sharps Bins
- Deciphex, a Dublin-based company to develop (AI)-based approaches with potential to transform preclinical pathology assessments in drug discovery
- Integrating physical activity into the patient journey in Ireland with ExWell Medical
- Collaborating with LetsGetChecked Lpa (health testing)



# Achievements and Ambitions<sup>4</sup>

**45%** female management (2024)<sup>3</sup>



**Only pharma company** to have signed the United Nations' Equal Pay International Coalition Pledge<sup>10</sup>

**Novartis Graduate Recruitment Programme & Work Placements**



CIRCA **20%** of Novartis Ireland employees hold a PhD<sup>3</sup>



and the company employees over

**50 nationalities<sup>2</sup>**




member of **Healthy Ireland Network**

# Green Achievements and Ambitions<sup>4</sup>

**1600 sharps bins** have been reused equivalent to making over **5 million cups of tea<sup>11</sup>** = avoid producing CO<sub>2</sub>



Elm Park Campus almost **100% single-use plastic free<sup>12</sup>**



**#2** pharma company and **17th out of 100** companies in Time Magazine's World's Most Sustainable Companies 2024<sup>13</sup>



Aim to be **water- and plastic-neutral** by 2030 and achieve **net zero carbon emissions** by 2040



**bike facilities** on-site



**eliminated 60,000 paper cups** per year from our office waste

Paper printing reduced globally by **71%** since **2016<sup>14</sup>**



ElmPark Green Campus is part of the **All Ireland Pollinator Plan**



**Electric Vehicle** charging points on-site. **E-Fleet of electric vehicles** now available for our teams

Aim to reduce vehicle fleet emissions by **90%** by 2030

# Societal Impact<sup>6</sup>

Our commitment is based on 4 pillars



Respecting and understanding the patient community perspective



Expanding access to our medicines



Conducting responsible clinical trials



Recognising the importance of transparency and reporting

## 1. Before a diagnosis

We have a global commitment to involve patients in the early stages of clinical trials.

**In the past 5 years:<sup>6</sup>**

- 87% of early research programs obtained patient insights before trials.
- 191 simplified trial documents for patients.

Digital tools supporting identification of symptoms of concern.



Heart Failure Symptom Checker.\*

Impactful campaigns and events raise public awareness.

Patient information meetings in oncology, cardiology and neurology.

**Tilda:** The primary objective of the research is to measure Lp(a) levels in the TILDA cohort. Health Related Quality of Life, at least one prior cardiac event, co-morbidities including ASCVD, CV, diabetes, and hypercholesterolemia.



Campaign to raise awareness for Rare Disease Day.†

## 2. At diagnosis



Our dedicated Supply Chain team ensures medicines have continued to reach people no matter what the circumstances.

Support and education of people with a new diagnosis and online resources.



**Oncology Nurse Service:** provides at home ECG/Bloods service to patients at home.



**Beacon Chemo Bike Project:** Novartis provided funding in 2023 for a stationary bike in an oncology ward to be used in research to understand impact of exercise before and during chemotherapy.

Arthritis Ireland



**Arthritis Ireland:** Novartis sponsors an Arthritis Ireland pilot study in which they are building a referral pathway for all non-clinical calls to be redirected from clinics to Arthritis Ireland.




**Irish Skin Foundation:** Novartis sponsors the ISF dermatology helpline, an important resource for people around Ireland living with skin conditions.

## 3. Ongoing Care



Ongoing support for patients provided by our Novartis Nurses with almost 1,600 people visited in hospital or their homes and almost 13,000 patient contacts in 2022.

Empowering people to self-manage psoriasis and multiple sclerosis.



Supporting people with how/when to take their medication.



Immune Thrombocytopenia (ITP) Pocket Log symptom and severity tracker.

## 4. Living Well

Providing support to help people live well with a diagnosis.



Creating a space for the patient perspective to be heard.



Patient Councils providing insights.



Societal Cost of MS.#

Helping create healthy communities.



Exercise classes for chronic disease and breast cancer.

# Clinical Trials in Ireland



clinical trials ranking  
in Ireland  
(no. of trials) **#5**<sup>15\*</sup>

**10** trials  
ongoing<sup>16</sup>



including trials in • breast cancer  
• multiple sclerosis  
• heart disease  
• immunology

annual investments  
in R&D (including clinical trials)  
over



**165** Ireland-based staff<sup>†</sup>  
and almost **€25m**<sup>16</sup>

across  
**34** trial sites

with approx.  
**240** patients<sup>‡</sup>

**€11 billion**  
invested globally in R&D  
in 2023<sup>17</sup>



\* Novartis is ranked fifth in Ireland in terms of absolute number of clinical trials, when compared to the nine other largest pharmaceutical companies.

† Staff involved in R&D or clinical trials (global and local).

‡ This number is an approximation as it includes both recruited patients and recruitment targets for ongoing trials.

## Pipeline<sup>18</sup>



New Indication<sup>†</sup>



New Molecule<sup>†</sup>

### 2025

ABT-627 Renal Disease	
LNP023 Renal conditions	
LOU064 Immunology	
177LU Prostate Cancer	
L01EA06 Chronic Myelogenous Leukemia	

### 2025-2027

TQJ230 Lp(a) Heart Disease	
AVXS-101 Spinal Muscular Atrophy	
siRNA Cardiovascular	

R&D = research and development

† The information above is indicative of potential pipeline currently under investigation by Novartis, which may or may not get regulatory approval.

References: 1. Novartis Data on File (SEE Impact Report 2023) 2. Novartis Data on File 3. Novartis Data on File 4. Novartis Data on File 5. Novartis Data on File 6. Novartis Data on File (SEE Impact Report 2023) 7. Novartis Data on File (SEE Impact Report 2023) 8. The Social Impact of Novartis Medicines in Ireland in 2023 from Wfor Institute. 9. Novartis Data on File. 10. <https://www.equalpayinternationalcoalition.org/sites/default/files/2024-01/EPIC%202023%20Compilation%20of%20Pledges.pdf>, Accessed October 9th 2024. 11. Novartis Data on File. 12. Novartis Data on File. 13. <https://time.com/collection/worlds-most-sustainable-companies-2024/> "World's Most Sustainable Companies 2024 | TIME, Accessed October 9th 2024. 14. Novartis Data on File. 15. <https://clinicaltrials.gov>, Accessed October 8th 2024. 16. Novartis Data on File. 17. Novartis Data on File. 18. <https://www.novartis.com/sites/novartis.com/files/2024-jpm-novartis-strategy-growth-update.pdf>, Accessed October 9th 2024.